DBV Technologies (NASDAQ:DBVT) Stock Price Crosses Below 200-Day Moving Average - What's Next?

Key Points

• DBV Technologies shares fell below their 200-day moving average, reaching $12.93 and last trading at $12.97 versus the $17.62 long-term average.
• Analyst sentiment remains mixed but leans positive: five analysts rate the stock Buy, one Hold, and one Sell, producing a “Moderate Buy” consensus and a $48.50 average price target.
• Institutional investors own 71.74% of the company, with several funds recently initiating or increasing positions, while DBV continues developing Viaskin Peanut and other needle-free allergy immunotherapies.

DBV Technologies S.A. (NASDAQ:DBVT - Get Free Report)'s share price crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $17.62 and traded as low as $12.93. DBV Technologies shares last traded at $12.97, with a volume of 125,350 shares trading hands.

Analyst Upgrades and Downgrades

DBVT has been the topic of several recent research reports. Citizens Jmp increased their price objective on shares of DBV Technologies from $47.00 to $55.00 and gave the stock a "market outperform" rating in a research note on Tuesday, June 30th. HC Wainwright restated a "buy" rating on shares of DBV Technologies in a research report on Tuesday, June 30th. Wall Street Zen cut shares of DBV Technologies from a "hold" rating to a "sell" rating in a report on Saturday, July 4th. Weiss Ratings downgraded shares of DBV Technologies from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Friday, July 17th. Finally, Cantor Fitzgerald reiterated an "overweight" rating on shares of DBV Technologies in a research note on Thursday. Five analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $48.50.

DBV Technologies Price Performance

The business has a 50-day simple moving average of $14.37 and a 200 day simple moving average of $17.62. The firm has a market cap of $815.55 million, a PE ratio of -3.70 and a beta of -0.95.

Institutional Investors Weigh In On DBV Technologies

Several hedge funds and other institutional investors have recently added to or reduced their stakes in DBVT. Truvestments Capital LLC increased its stake in shares of DBV Technologies by 71.3% in the fourth quarter. Truvestments Capital LLC now owns 3,892 shares of the company's stock worth $75,000 after purchasing an additional 1,620 shares in the last quarter. Allworth Financial LP purchased a new position in shares of DBV Technologies during the 4th quarter valued at $32,000. Royal Bank of Canada purchased a new position in shares of DBV Technologies during the 4th quarter valued at $34,000. Persistent Asset Partners Ltd bought a new position in DBV Technologies in the 4th quarter worth $115,000. Finally, Cetera Investment Advisers boosted its stake in shares of DBV Technologies by 93.4% in the first quarter. Cetera Investment Advisers now owns 25,358 shares of the company's stock worth $530,000 after acquiring an additional 12,243 shares during the period. 71.74% of the stock is owned by hedge funds and other institutional investors.

DBV Technologies Company Profile

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.